{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:12:41Z","timestamp":1784747561155,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100022656","name":"University Hospital Centre Nimes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022656","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bulcan.2026.03.005","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:47:34Z","timestamp":1778820454000},"page":"946-949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality-of-life trajectories in advanced urothelial carcinoma patients under pembrolizumab: Results from the French AMI observational cohort trial"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0387-2261","authenticated-orcid":false,"given":"Soufyan","family":"Annakib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Di M\u00e9glio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Hou\u00e9d\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Fiteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bulcan.2026.03.005_bib0055","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bulcan.2026.03.005_bib0060","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.005_bib0065","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.euo.2023.05.001","article-title":"Quality of life with monoclonal antibody therapies for locally advanced or metastatic urothelial carcinoma: a systematic review","volume":"6","author":"Annakib","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2026.03.005_bib0070","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/jcm10091852","article-title":"Patient-reported outcomes, health-related quality of life, and clinical outcomes for urothelial cancer patients receiving chemo- or immunotherapy: a real-life experience","volume":"10","author":"Taarnh\u00f8j","year":"2021","journal-title":"JCM"},{"issue":"8","key":"10.1016\/j.bulcan.2026.03.005_bib0075","doi-asserted-by":"crossref","first-page":"e70896","DOI":"10.1002\/cam4.70896","article-title":"Patient versus clinician reported symptoms agreement in advanced metastatic bladder cancer patients","volume":"14","author":"Annakib","year":"2025","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.bulcan.2026.03.005_bib0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000526962","article-title":"Prospective evaluation of health-related quality of life in patients with metastatic urothelial carcinoma undergoing immunotherapy with pembrolizumab: symptom burden can predict survival","volume":"107","author":"Schneidewind","year":"2023","journal-title":"Urol Int"},{"issue":"3","key":"10.1016\/j.bulcan.2026.03.005_bib0085","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.euo.2020.02.009","article-title":"Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer (KEYNOTE-052): outcomes in older patients by age and performance status","volume":"3","author":"Grivas","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2026.03.005_bib0090","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s11523-024-01089-2","article-title":"Pembrolizumab in patients with advanced urothelial carcinoma with ECOG Performance Status 2: a real-world study from the ARON-2 project","volume":"19","author":"Rizzo","year":"2024","journal-title":"Targ Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2026.03.005_bib0095","first-page":"100908","article-title":"Durvalumab in patients with treatment-naive stage IV NSCLC with an ECOG performance status of 2 to 3 and high PD-L1 tumor expression (IFCT-1802 SAVIMMUNE): a multicenter phase 2 trial","volume":"6","author":"Gounant","year":"2025","journal-title":"JTO Clin Res Rep"},{"issue":"4","key":"10.1016\/j.bulcan.2026.03.005_bib0100","doi-asserted-by":"crossref","first-page":"e225118","DOI":"10.1001\/jamanetworkopen.2022.5118","article-title":"Characterization of depressive symptoms trajectories after breast cancer diagnosis in women in France","volume":"5","author":"Charles","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126002213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126002213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:57:33Z","timestamp":1784746653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126002213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":10,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0007455126002213"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.03.005","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality-of-life trajectories in advanced urothelial carcinoma patients under pembrolizumab: Results from the French AMI observational cohort trial","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}